GlassScriptPhysician profile
Hannah M Hall
NPI 1124343934
$2,573.18
in general payments reported to CMS, 2019-2025
29 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $239 · 2021: $287 · 2022: $414 · 2023: $444 · 2024: $603 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.53 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.94 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $295.79 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $261.91 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $255.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $155.65 | 2022-2025 | |
| Abbott Laboratories | $119.49 | 2021-2022 | |
| Amgen INC. | $94.27 | 2019-2025 | Evenity, Prolia |
| Gilead Sciences, INC. | $89.95 | 2023 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $89.71 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $85.56 | 2019-2022 | |
| Insmed, INC. | $83.06 | 2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.96 | 2020-2021 | |
| Astellas Pharma US INC | $70.07 | 2020-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $65.85 | 2022-2025 | |
| Pfizer INC. | $64.11 | 2020-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.98 | 2019-2022 | |
| Exact Sciences Corporation | $49.29 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $36.66 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $33.69 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.59 | 2022-2024 | Eliquis |
| Boston Scientific Corporation | $27.12 | 2024 | Watchman Flx |
| Jazz Pharmaceuticals INC. | $21.80 | 2022 | |
| Organon LLC | $21.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $19.34 | 2022 | |
| Alkermes, INC. | $17.46 | 2022 | |
| Eisai INC. | $12.95 | 2020 | |
| Tactile Systems Technology INC | $12.40 | 2019 | |
| Grifols USA, LLC | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.